MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We are excited to announce the formation of this partnership with Regenity and believe it is an important step toward achieving our long-term growth plan.
- Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We are excited to announce the formation of this partnership with Regenity and believe it is an important step toward achieving our long-term growth plan.
- As we have stated, one of our strategic priorities is to augment our best-in-class placental-derived product portfolio with xenografts and/or synthetic skin substitutes in order to meet the needs of a greater number of customers, domestically and abroad.
- The collagen in this product serves as a dressing that allows for cell adhesion and migration into the wound site and supports wound healing.
- “Additionally, we look forward to partnering with Regenity and leveraging their expertise to bring other products in our pipeline to market in the future.